SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as it hits a 12-year low, with the community sharply divided over whether the stock represents a deep-value opportunity for patient dividend seekers or a failing brand facing long-term structural decline. Investors are debating the impact of aggressive short-selling activity and leadership skepticism against the potential for an eventual turnaround.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors weigh strong revenue growth projections against concerns over potential share dilution and a lack of transparency regarding earnings release dates. The community remains deeply divided, with bulls pointing to the company's expansion into AI infrastructure as a massive long-term catalyst, while bears emphasize historical volatility and management's reliance on convertible financing.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is drawing significant investor interest following a strong quarterly earnings report that featured a revenue and EPS beat alongside a raised outlook, confirming robust demand for its AI optical packaging services. While the community is actively debating the company's premium valuation and negative free cash flow metrics, many long-term shareholders remain bullish, viewing the recent volatility as an opportunity for entry amid the ongoing buildout of AI and hyperscale infrastructure.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is capturing market attention as its modular edge data center business scales, fueled by a high-value $500 million hosting agreement with Axe Compute and consistent revenue growth. Community sentiment remains bullish on the company's ability to navigate infrastructure bottlenecks, though some investors are closely monitoring the capital-intensive nature of its rapid expansion and potential for future equity dilution.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is surging on significant investor enthusiasm following the FDA approval of its lead drug, Komzifti, with the community highlighting its best-in-class safety profile and once-daily dosing as key advantages over competitors. The conversation is heavily focused on the company's strong institutional backing, healthy cash reserves, and the potential for a transformative 2026 as it pushes into frontline AML indications and expands its solid tumor pipeline.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing intense volatility and active retail participation as the community debates whether the stock's recent price swings are driven by legitimate AI infrastructure demand or artificial momentum aimed at future share offerings. Traders are heavily focused on the stock's low float and the ongoing battle between those capitalizing on parabolic intraday moves and those positioning for a potential long-term reversal.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is trending as investors focus on the upcoming Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, with recent analyst upgrades and institutional positioning driving strong sentiment. Community discussions are centered on the company's solid cash runway extending through 2028 and the potential for a transformative impact in the underserved metabolic and endocrine markets.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as retail investors rally behind the company's aggressive patent enforcement and licensing strategy, fueled by optimism over recent legal settlements and upcoming court hearings. The community is actively discussing potential major catalysts, such as impending patent rulings and high-profile litigation, while debating whether current price action signals a long-term valuation shift or a short squeeze opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors digest the company's progress toward a Q4 2026 NDA submission for AXPAXLI, a catalyst further bolstered by FDA alignment that removes the requirement for SOL-R efficacy data. While bullish community sentiment focuses on the companys potential to disrupt the wet AMD market and its status as a high-conviction buyout candidate, discussions remain polarized by persistent debates over trial design, competitive dynamics with EyePoint Pharmaceuticals, and the impact of the company's short interest.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is currently trending as investors weigh its attractive valuation and strong brand presence against concerns over retail sector headwinds and leadership transitions. While some market participants see an entry point for a potential turnaround, others are voicing caution regarding mounting competition and shifting consumer spending habits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

AXKAccelr8 Technology Corp.

Connect Stocktwits to ChatGPT

Latest AXK News